title: Subconjunctival Bevacizumab for the Treatment of Keratoprosthesis-Associated Cystoid Macular Edema.
abstract: The authors present a case of keratoprosthesis-associated cystoid macular edema (CME) responsive to subconjunctival bevacizumab (Avastin; Genentech, South San Francisco, CA). A 40-year-old woman with a history of Stevens-Johnson syndrome (SJS) and Boston keratoprosthesis type I implantation developed CME 10 months after surgery and received sub-Tenon's kenalog with minimal improvement. Sixteen months after surgery, she received a subconjunctival injection of bevacizumab and demonstrated visual and anatomic improvement. Ten weeks later, she received a second subconjunctival injection of bevacizumab for worsening CME and again demonstrated a favorable response. Subconjunctival bevacizumab may be an effective and less-invasive alternative to intravitreal injections for the treatment of postoperative CME.
authors.forename: Nora W
authors.initials: NW
authors.lastname: Muakkassa
authors.forename: Kendra A
authors.initials: KA
authors.lastname: Klein
authors.forename: Pedram
authors.initials: P
authors.lastname: Hamrah
authors.forename: Elias
authors.initials: E
authors.lastname: Reichel
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001187:Artificial Organs; D000068258:Bevacizumab / Q000627:therapeutic use*; D001705:Bioprosthesis / Q000009:adverse effects*; D003228:Conjunctiva; D003315:Cornea; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D056965:Injections, Intraocular; D008269:Macular Edema / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab